Global InformationCrenezumab information
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | 1-40-β-amyloid |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number |
|
| ChemSpider |
|
| UNII |
|
| KEGG |
|
| Chemical and physical data | |
| Formula | C6442H9966N1706O2018S40 |
| Molar mass | 144884.91 g·mol−1 |
  (what is this?) (verify) | |
Crenezumab is a fully humanized monoclonal antibody against human 1-40 and 1-42 beta amyloid, which is being investigated as a treatment of Alzheimer's disease.[1] Crenezumab is highly homologous to solanezumab, another monoclonal antibody targeting amyloid-β peptides.[2] In June 2022, the US National Institutes of Health announced that the drug failed as a medication for early-onset Alzheimer's disease following the results of a decade-long clinical trial.[3]
- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Crenezumab" (PDF). American Medical Association.
- ^ Crespi GA, Hermans SJ, Parker MW, Miles LA (April 2015). "Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies". Scientific Reports. 5: 9649. Bibcode:2015NatSR...5E9649C. doi:10.1038/srep09649. PMC 4549621. PMID 25880481.
- ^ Hodes, Richard J. (16 June 2022). "NIA statement on crenezumab trial results: Anti-amyloid drug did not demonstrate a statistically significant clinical benefit in people with inherited form of Alzheimer's disease". National Institute on Aging. Retrieved 22 June 2022.